Beremagene geperpavec is a gene therapy commercialized by Krystal Biotech, with a leading Pre-Registration program in Epidermolysis Bullosa. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Beremagene geperpavec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Beremagene geperpavec is expected to reach an annual total of $540 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Beremagene geperpavec Overview

Beremagene geperpavec is under development for the treatment of dystrophic epidermolysis bullosa (DEB). The drug candidate is a replication-defective, non-integrating viral vector engineered using STAR-D (skin TARgeted delivery) platform to deliver functional human COL7A1 genes. It is administered through a topical route formulated as gel. The STAR-D platform consists of an engineered viral vector based on herpes simplex virus 1.

Krystal Biotech Overview

Krystal Biotech is a gene therapy company that develops and commercializes treatments for dermatological diseases. The company’s product pipeline includes B-VEC (bercolagene telserpavec) gene therapy, against dystrophic epidermolysis bullosa (DEB); KB105 therapy, targeting autosomal recessive congenital ichthyosis (ARCI), a genetic skin disease caused due to deficiency of TGM1 gene. It is also investigating KB301, to treat aesthetic skin conditions; KB104, against Netherton Syndrome; KB107, for the treatment of Junctional Epidermolysis Bullosa (JEB); and KB5XX, targeting chronic skin diseases. The company utilizes the skin TARgeted Delivery (STAR-D) platform to develop treatments for skin diseases. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, the US.

The operating loss of the company was US$68.3 million in FY2021, compared to an operating loss of US$33 million in FY2020. The net loss of the company was US$69.6 million in FY2021, compared to a net loss of US$32.2 million in FY2020.

For a complete picture of Beremagene geperpavec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.